New Strong Sell Stocks for July 23rd

Zacks has added Alaska Air Group (ALK), HF Sinclair Corporation (DINO), and Ironwood Pharmaceuticals (IRWD) to its Rank #5 (Strong Sell) List. This designation stems from significant downward revisions to their current year earnings estimates over the past 60 days, with HF Sinclair experiencing the largest revision at 28.1%, Alaska Air at 3.4%, and Ironwood Pharmaceuticals at 8.2%, signaling potential underperformance.

Analysis

Three companies across distinct sectors—Alaska Air Group (ALK), HF Sinclair Corporation (DINO), and Ironwood Pharmaceuticals (IRWD)—have been downgraded to a Zacks Rank #5, signifying a 'Strong Sell' rating. This action is predicated on significant downward revisions to their respective Zacks Consensus Estimates for current year earnings over the past 60 days. The magnitude of these revisions varies, with HF Sinclair experiencing the most severe cut at 28.1%, followed by Ironwood Pharmaceuticals at 8.2% and Alaska Air at 3.4%. These revisions indicate a material deterioration in the earnings outlook as perceived by covering analysts, which is further corroborated by the highly negative per-ticker sentiment scores of -0.9 for DINO, -0.8 for IRWD, and -0.7 for ALK. The substantial cut for energy company HF Sinclair suggests a particularly sharp negative shift in its fundamental forecast.

Key Decisions for Investors

• Investors with existing long positions in ALK, DINO, and IRWD should re-evaluate their holdings, as the 'Strong Sell' rating and negative earnings revisions signal potential for underperformance.
• The significant 28.1% downward earnings revision for HF Sinclair (DINO) makes it a candidate for further due diligence for potential short-side trades, reflecting the most severe negative sentiment among the group.
• It is prudent to avoid initiating new long positions in these three stocks until there is a clear stabilization or positive reversal in their earnings estimate trends.
• Investors should monitor upcoming earnings reports from these companies closely for management guidance that could either validate or contradict the recent negative analyst consensus.